S
Siglinde Wolf
Researcher at Max Planck Society
Publications - 10
Citations - 766
Siglinde Wolf is an academic researcher from Max Planck Society. The author has contributed to research in topics: Small molecule & MDMX. The author has an hindex of 10, co-authored 10 publications receiving 725 citations.
Papers
More filters
Journal ArticleDOI
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery
Grzegorz M. Popowicz,Anna Czarna,Siglinde Wolf,Kan Wang,Wei Wang,Alexander Dömling,Tad A. Holak +6 more
TL;DR: The structures indicate how the substituents of a small molecule that bind to the three subpockets of theMDM2/X-p53 interaction should be optimized for effective binding to MDM2 and/or MDMX.
Journal ArticleDOI
Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists
Journal ArticleDOI
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx
TL;DR: The structural information presented here, coupled with the robust fluorescence polarization assay, should enable development of a simple pharmacophore model of cross-selective Mdm2-Mdmx/p53 inhibitors.
Journal ArticleDOI
Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
David Ryan Koes,Kareem Khoury,Yijun Huang,Wei Wang,Michal Bista,Grzegorz M. Popowicz,Siglinde Wolf,Tad A. Holak,Alexander Dömling,Carlos J. Camacho +9 more
TL;DR: A novel pharmacophore-based interactive screening technology that builds on the role anchor residues, or deeply buried hot spots, have in PPIs, and redesigns these entry points with anchor-biased virtual multicomponent reactions, delivering tens of millions of readily synthesizable novel compounds.
Journal ArticleDOI
1,4-Thienodiazepine-2,5-diones via MCR (I): Synthesis, Virtual Space and p53-Mdm2 Activity
Yijun Huang,Siglinde Wolf,Michal Bista,Lidio Meireles,Carlos J. Camacho,Tad A. Holak,Alexander Dömling +6 more
TL;DR: 1,4‐Thienodiazepine‐2,5‐diones have been synthesized via the Ugi‐Deprotection‐Cyclization (UDC) approach starting from Gewald 2‐aminothiophenes in a convergent and versatile manner and some compounds exhibited promising antagonistic activity.